GBT - Global Blood Therapeutics, Inc.
| Previous Close | 63.00 |
| Open | 63.07 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 900 |
| Day's Range | 62.74 - 64.89 |
| 52 Week Range | 30.15 - 64.89 |
| Volume | 1,150,793 |
| Avg. Volume | 767,298 |
| Market Cap | 3.57B |
| Beta (3Y Monthly) | 1.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.41 |
| Earnings Date | Jul 31, 2019 - Aug 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 91.23 |
- Simply Wall St.•2 days ago
Should You Be Concerned About Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) Historical Volatility?
If you're interested in Global Blood Therapeutics, Inc. (NASDAQ:GBT), then you might want to consider its beta (a...
- Insider Monkey•6 days ago
Is Global Blood Therapeutics Inc (GBT) A Good Stock To Buy?
Before we spend countless hours researching a company, we'd like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- Schaeffer's Investment Research•11 days ago
Global Blood Therapeutics Stock Options Hot During Sell-Off
Guggenheim says to buy the stock's dip
- GlobeNewswire•11 days ago
GBT Announces Updated 24-Week Efficacy Data from All Patients Enrolled in Phase 3 HOPE Study Showing Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor
Global Blood Therapeutics, Inc. (GBT) (GBT) today announced new results from its Phase 3 HOPE Study of voxelotor in patients ages 12 and older with sickle cell disease (SCD). The findings from 274 adolescents and adults treated with voxelotor showed the HOPE Study met its primary endpoint of an improvement in hemoglobin greater than 1 g/dL at 24 weeks with voxelotor 1500 mg compared with placebo, with a favorable safety and tolerability profile.
- Zacks•12 days ago
Options Traders Expect Huge Moves in Global Blood Therapeutics (GBT) Stock
Investors need to pay close attention to Global Blood Therapeutics (GBT) stock based on the movements in the options market lately.
- Motley Fool•12 days ago
A Biotech Stock to Watch Now
Investors will get additional insight into a potential new treatment for sickle cell disease on Friday.
- GlobeNewswire•15 days ago
GBT Awards More than $200,000 in Grants to Five Nonprofit Organizations through New ACCEL Program Aimed at Improving Access to Healthcare for People Living with Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., June 10, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that five nonprofit organizations have been awarded more than.
- Zacks•18 days ago
Why Is Global Blood (GBT) Up 2% Since Last Earnings Report?
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire•18 days ago
GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., June 07, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2019, the compensation committee of GBT’s.
- GlobeNewswire•last month
GBT Announces Upcoming Data Presentations at 24th European Hematology Association (EHA) Congress Supporting Voxelotor Sickle Cell Disease Program
Phase 3 HOPE Study 24-Week Efficacy Results from Full Patient Cohort to be Presented During Presidential Symposium New Drug Application (NDA) Submission Planned for Voxelotor.
- Zacks•2 months ago
Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1
Global Blood (GBT) reports narrower-than-expected loss in the first quarter of 2019.
- Associated Press•2 months ago
Global Blood: 1Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of 87 cents per share. The results surpassed Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment ...
- GlobeNewswire•2 months ago
GBT Reports Recent Business Progress and First Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., May 08, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the first.
- Simply Wall St.•2 months ago
When Will Global Blood Therapeutics, Inc. (NASDAQ:GBT) Breakeven?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Global Blood Therapeutics, Inc.'s (NASDAQ:GBT): Global Blood Therapeutics, Inc., a clinical-sta...
- Insider Monkey•2 months ago
Did Hedge Funds Drop The Ball On Global Blood Therapeutics Inc (GBT) ?
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
- GlobeNewswire•3 months ago
GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., April 02, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the H.C. Wainwright Global Life.
- Simply Wall St.•4 months ago
Announcing: Global Blood Therapeutics (NASDAQ:GBT) Stock Increased An Energizing 211% In The Last Three Years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can make much more than 100% if theRead More...
- GlobeNewswire•4 months ago
Detailed Research: Economic Perspectives on Intelsat S.A, Sprint, Restaurant Brands International, Tower Semiconductor, TE Connectivity, and Global Blood Therapeutics — What Drives Growth in Today's Competitive Landscape
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- GlobeNewswire•4 months ago
GBT Announces Participation at the Cowen and Company 39th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 04, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the Cowen and Company 39th Annual.
- American City Business Journals•4 months ago
Aiming at genetic diseases, Peninsula stealth biotech emerges with $191 million
The startup is tapping a wealth of genetic information in databases and a new wave of technology in its quest to figure out why some people with a genetic mutation can have a more-severe form of a disease than others with the same mutation.
- GlobeNewswire•4 months ago
GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the fourth.
- GlobeNewswire•4 months ago
GBT Announces Participation at the 8th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 8th Annual SVB Leerink Global.
